30 junio 2020

Pharmamar está buscando cotizar en el Nasdaq con el objetivo de aprovechar el voraz apetito de los inversores por el sector mientras prueba una de sus terapias para tratar COVID-19 Nasdaq's $1.2 trillion biotech index draws Europe's COVID drug hunters.

MADRID/LONDON - 

Spain Pharma Mar <PHMR.MC> is looking at listing on New York's Nasdaq market, joining a flurry of biotech companies aiming to tap investors' voracious appetite for the sector as it tests one of its therapies to treat COVID-19.

The move comes several weeks after the company started mid-stage human trials of cancer drug Aplidin in COVID-19 patients.

The preliminary tests were "super encouraging", although the sample is still too small to be statistically significant, Chairman Jose Maria Fernandez Sousa-Faro told Reuters.

Pharma Mar's Madrid shares have almost tripled to 7.51 euros ($8.41) since mid March, taking its market valuation to 1.67 billion euros ($1.87 billion).

The pharma industry's search for a treatment for COVID-19 has sparked a parallel hunt among investors for the companies most likely to succeed.

That has seen the Nasdaq's biotech index <.NBI> soar about 25% in the second quarter, its best quarterly performance in nearly 20 years, to reach a total value of $1.2 trillion.

...